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What you need to know:

**Background and Context:** Firmicutes bacteria produce metabolites that help maintain the intestinal barrier and mucosal immunity. Firmicutes and their associated metabolites are reduced in intestinal microbiota of patients with ulcerative colitis (UC).

**New Findings**: In a phase 1b trial, administration of SER-287 (Firmicutes spores) following vancomycin preconditioning induced clinical remission in a significantly higher proportion of patients with mild to moderately active UC than placebo. The safety and tolerability of SER-287 were similar to those of placebo.

**Limitations**: This was a small study of limited duration (12 weeks)---larger studies are needed.

**Impact**: SER-287 may induce remission by changing the composition and function of the gut microbiome.

**Lay Summary**: The authors identified a community of bacteria that are reduced in the intestinal microbiomes of patients with UC but when given orally (in spore form) induces remission in about 40% of patients.
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